NCT00882869 - XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

March 31, 2011

Study Completion Date

May 31, 2011

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG

AEG35156 antisense IV infusion

Dose escalation (100, 200 and 300 mg/day) over 2 hr infusion, once weekly over 21 days (Day 1, 8, 15)

DRUG

Sorafenib

Sorafenib will be administered at 400 mg BID every day

Trial Locations (3)

Tuen Mun Hospital, Tuenmen

Queen Elizabeth Hospital, Hong Kong

Queen Mary Hospital, Hong Kong